Company: Anavex Life Sciences Corp.
Location: US – New York
Drug Type: Small Molecule
Conditions: ALS, Alzheimer’s disease, Parkinson’s disease and other neurodevelopmental disorders.
Mechanism Type: Sigma-1 receptor (S1R) and Muscarinic receptor agonist
Mechanism: ANAVEX 2-73, is a sigma-1 and muscarinic receptor agonist. The sigma-1 receptors are chaperone proteins localized to the endoplasmic reticulum (ER) membrane associated with mitochondria (MAMs), and function by helping protect against ER and oxidative stress. The sigma-1 receptors have been implicated in several neurodegenerative diseases, including ALS.
U.S. Status for ALS: Preclinical
 Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig’s Disease). GlobeNewswire, 10 Mar 2014. Accessed 3 Mar 2016 from https://globenewswire.com/news-release/2014/03/10/616981/10071871/en/Anavex-Encouraged-By-Scientific-Data-Confirming-Sigma-1-Receptor-Agonist-Extends-Survival-in-ALS-Lou-Gehrig-s-Disease.html.
 Role of the Sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS) Mavlyutov, TA et al. J Pharmacol Sci. 2015 Jan;127(1):10-6.
Last updated March 3rd, 2016